But surprisingly, this combination therapy reshaped the immune microenvironment of tumor-bearing mice, including inhibiting the accumulation of MDSCs, promoting the proportion of M1 macrophages, CD4+ T and CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.